London, Feb 23, 2026, 09:18 GMT — Regular session
- Haleon edges up roughly 0.1% to 409.9 pence early in the London session
- Full-year 2025 results land Wednesday; traders watching for any signals on the 2026 outlook.
- The company had previously pointed to organic sales growth of about 3.5% for 2025, while also highlighting a currency headwind.
Haleon shares ticked up around 0.1% to 409.9 pence on Monday, fluctuating between 409.39 and 412.50 pence during the session. The stock sits roughly 2% shy of its 52-week peak, having traded in a band from 325.10 to 419.40 pence over the last year.
Haleon is set to deliver its full-year 2025 numbers this Wednesday, ahead of its Q1 trading update slated for April 29. Investors will be combing through the results for fresh clues on sales traction, cash distributions, and any signal on how 2026 guidance is shaping up.
Haleon, in a January “aide-memoire” circulated before its results, stuck with its outlook: about 3.5% organic revenue growth for 2025, provided the cold and flu season sticks to normal patterns. That’s organic, so it cuts out the noise from currency moves and deals. The same document highlighted a roughly 2.8% negative currency impact on net revenue and a 3.8% hit on adjusted operating profit, both calculated using Bloomberg FX rates at the time. Haleon also noted it expects to complete a £500 million share buyback allocation next year. Haleon Corporate
Haleon, behind familiar brands like Sensodyne, Panadol, Advil, and Voltaren, offers a lineup spanning pain relief and oral care. The consumer health company trades on both the London and New York exchanges.
Executives have called out internal changes as well. Back in January, Haleon announced a restructuring of its operating model, rolling out a Chief Growth Officer position and reorganizing into six operating units, aiming to have it all in place by mid-2026. CEO Brian McNamara described the revamp as a move to make the company “simpler and more agile and efficient”. Haleon Corporate
Wednesday’s results are expected to come down to the fundamentals. Organic sales growth, adjusted profit margins, and free cash flow usually get the most attention from investors. Debt targets matter too, plus how fast the company converts sales growth into cash.
Seasonal swings matter for a company tied to cold-and-flu trends. Haleon points out that even minor changes during a typical season can have an outsized impact—sometimes enough to show up in the basis points, with 100 basis points making up a full percentage point.
Currency swings matter too, particularly for a company pulling in a large chunk of sales abroad before converting back to its reporting currency. Should the pound strengthen, headline growth takes a hit—even if local prices and volumes stay solid.
Still, tone could prove just as crucial as the raw numbers here. If the 2026 outlook softens or it looks like market share gains are coming from deeper promotions, that could unsettle a stock hovering near its yearly peak—especially if investors feel they’ve already priced in more consistent demand.
